WallStSmart

Basel Medical Group Ltd Ordinary Shares (BMGL)vsHCA Healthcare, Inc. (HCA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

HCA Healthcare, Inc. generates 518273% more annual revenue ($76.39B vs $14.74M). HCA leads profitability with a 8.9% profit margin vs -68.2%. HCA earns a higher WallStSmart Score of 63/100 (C+).

BMGL

Hold

38

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.0
Piotroski: 3/9Altman Z: -1.69

HCA

Buy

63

out of 100

Grade: C+

Growth: 5.3Profit: 8.0Value: 5.3Quality: 6.0
Piotroski: 5/9Altman Z: 1.71
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BMGL.

HCASignificantly Overvalued (-85.1%)

Margin of Safety

-85.1%

Fair Value

$287.10

Current Price

$395.79

$108.69 premium

UndervaluedFair: $287.10Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BMGL2 strengths · Avg: 9.0/10
Revenue GrowthGrowth
67.1%10/10

Revenue surging 67.1% year-over-year

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

HCA5 strengths · Avg: 9.0/10
Return on EquityProfitability
136.3%10/10

Every $100 of equity generates 136 in profit

Debt/EquityHealth
-7.4210/10

Conservative balance sheet, low leverage

Market CapQuality
$82.50B9/10

Large-cap with strong market position

P/E RatioValuation
12.8x8/10

Attractively priced relative to earnings

Free Cash FlowQuality
$1.10B8/10

Generating 1.1B in free cash flow

Areas to Watch

BMGL4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$8.80M3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.573/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

HCA2 concerns · Avg: 4.0/10
Revenue GrowthGrowth
4.3%4/10

4.3% revenue growth

Altman Z-ScoreHealth
1.714/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : BMGL

The strongest argument for BMGL centers on Revenue Growth, Price/Book. Revenue growth of 67.1% demonstrates continued momentum.

Bull Case : HCA

The strongest argument for HCA centers on Return on Equity, Debt/Equity, Market Cap. PEG of 1.20 suggests the stock is reasonably priced for its growth.

Bear Case : BMGL

The primary concerns for BMGL are EPS Growth, Market Cap, Debt/Equity. Debt-to-equity of 1.57 is elevated, increasing financial risk.

Bear Case : HCA

The primary concerns for HCA are Revenue Growth, Altman Z-Score.

Key Dynamics to Monitor

BMGL profiles as a hypergrowth stock while HCA is a value play — different risk/reward profiles.

BMGL is growing revenue faster at 67.1% — sustainability is the question.

HCA generates stronger free cash flow (1.1B), providing more financial flexibility.

Monitor MEDICAL CARE FACILITIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

HCA scores higher overall (63/100 vs 38/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Basel Medical Group Ltd Ordinary Shares

HEALTHCARE · MEDICAL CARE FACILITIES · USA

Basel Medical Group Ltd provides healthcare services. The company is headquartered in Singapore.

Visit Website →

HCA Healthcare, Inc.

HEALTHCARE · MEDICAL CARE FACILITIES · USA

HCA Healthcare is an American for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owns and operates 186 hospitals and approximately 2,000 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 21 states and the United Kingdom.

Visit Website →

Want to dig deeper into these stocks?